163 related articles for article (PubMed ID: 34455749)
41. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
42. CD4
Dong Y; Li X; Zhang L; Zhu Q; Chen C; Bao J; Chen Y
BMC Immunol; 2019 Aug; 20(1):27. PubMed ID: 31390978
[TBL] [Abstract][Full Text] [Related]
43. Combination Immune Checkpoint Blockade to Reverse HIV Latency.
Van der Sluis RM; Kumar NA; Pascoe RD; Zerbato JM; Evans VA; Dantanarayana AI; Anderson JL; Sékaly RP; Fromentin R; Chomont N; Cameron PU; Lewin SR
J Immunol; 2020 Mar; 204(5):1242-1254. PubMed ID: 31988180
[TBL] [Abstract][Full Text] [Related]
44. On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection.
Richter K; Agnellini P; Oxenius A
Int Immunol; 2010 Jan; 22(1):13-23. PubMed ID: 19880580
[TBL] [Abstract][Full Text] [Related]
45. The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma.
Chen H; Wang M; Weng T; Wei Y; Liu C; Yang L; Ren K; Tang Y; Tang Z; Gou X
Urol Oncol; 2021 Nov; 39(11):743-753. PubMed ID: 34330653
[TBL] [Abstract][Full Text] [Related]
46. Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD mice.
Vazquez-Mateo C; Collins J; Fleury M; Dooms H
BMC Immunol; 2017 Mar; 18(1):18. PubMed ID: 28356069
[TBL] [Abstract][Full Text] [Related]
47. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Zahran AM; Hetta HF; Rayan A; Eldin AS; Hassan EA; Fakhry H; Soliman A; El-Badawy O
Cancer Immunol Immunother; 2020 Jul; 69(7):1253-1263. PubMed ID: 32170378
[TBL] [Abstract][Full Text] [Related]
48. Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations.
Sun H; Sun C; Xiao W
Cytokine; 2014 Jan; 65(1):33-41. PubMed ID: 24139237
[TBL] [Abstract][Full Text] [Related]
49. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.
Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M
J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915
[TBL] [Abstract][Full Text] [Related]
50. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
[TBL] [Abstract][Full Text] [Related]
51. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
52. Highly proliferative and functional PD-1
Batorov EV; Aristova TA; Pronkina NV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Shevela EY; Ostanin AA; Chernykh ER
Int Immunopharmacol; 2021 Nov; 100():108093. PubMed ID: 34474273
[TBL] [Abstract][Full Text] [Related]
53. Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment.
Juno JA; Stalker AT; Waruk JL; Oyugi J; Kimani M; Plummer FA; Kimani J; Fowke KR
Retrovirology; 2015 Feb; 12():17. PubMed ID: 25810006
[TBL] [Abstract][Full Text] [Related]
54. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
55. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
[TBL] [Abstract][Full Text] [Related]
56. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
57. Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients.
Xia Q; Wei L; Zhang Y; Sheng J; Wu W; Zhang Y
Mediators Inflamm; 2018; 2018():1632902. PubMed ID: 30595665
[TBL] [Abstract][Full Text] [Related]
58. Programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) regulate CD4+ T cells to induce Type 2 helper T cell (Th2) bias at the maternal-fetal interface.
Wang S; Zhu X; Xu Y; Zhang D; Li Y; Tao Y; Piao H; Li D; Du M
Hum Reprod; 2016 Apr; 31(4):700-11. PubMed ID: 26908841
[TBL] [Abstract][Full Text] [Related]
59. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
60. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
Lee J; Han Y; Wang W; Jo H; Kim H; Kim S; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
